# GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

> **NCT07132112** · EARLY_PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 30 (estimated)

## Conditions studied

- Auto Immune Disease

## Interventions

- **BIOLOGICAL:** GT719 Injection

## Key facts

- **NCT ID:** NCT07132112
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-28
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132112, "GT719 Injection for Moderate to Severe Refractory Autoimmune Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07132112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*